echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The first Claudin 18.2/PD-L1 double antibody was approved for clinical use

    The first Claudin 18.2/PD-L1 double antibody was approved for clinical use

    • Last Update: 2021-04-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 4, the Center for Drug Evaluation (CDE) of the State Food and Drug Administration announced on its official website that the clinical trial application for the new drug "Q-1802 freeze-dried powder injection" of Qiyu Biologics has obtained clinical implied permission, and the indication is advanced solid tumors.


    Q-1802 is a bispecific antibody that is independently developed by Qiyu Biologics using its antibody engineering technology platform and has independent intellectual property rights that can simultaneously target PD-L1 and Claudin 18.


    On March 1, the US FDA also approved the IND application for Q-1802, the world's first Claudin 18.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.